Predict both clinical risk and tumor aggressiveness
Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+41-3.
Interactive report guide
Quickly and easily understand how to interpret the Genomic Prostate Score report.
See sample reports
For patients with:
How do you use the GPS™ report? The value of the GPS™ assay.
Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS report in his practice.
Getting your results
Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Exact Sciences Laboratory. You can access the results through the online physician portal or receive the report by fax.
Compare Report Results